Lower Pharmacy Costs Give Ruxolitinib Edge for Patients With MF and Anemia
Authors found the pharmacy costs for momelotinib were $11,095 higher per month, too much to offset higher transfusion costs for ruxolitinib.
The clinical benefits and lower transfusion costs of momelotinib (Ojjaara) are not enough to offset its higher pharmacy costs compared with an older therapy for patients with myelofibrosis (MF) and anemia who rely on transfusions, according to a recent cost-effectiveness analysis.
The results were presented in a poster at the 16th International Congress on Myeloproliferative Neoplasms, held in Brooklyn, New York, October 24-25, 2024.1
Led by Aaron T. Gerds, MD, MS, assistant professor of Medicine, Cleveland Clinic Taussig Cancer Institute, the authors presented data based on a predictive model that computed per-patient total cost of care for 6-month, 1-year, and 2-year periods, comparing the Janus kinase (JAK) inhibitors ruxolitinib (Jakafi), and momelotinib (Ojjaara). Both inhibit the JAK/STAT pathway, with momelotinib additionally targeting a pathway that can result in improved iron-restricted anemia.
As the poster authors stated, ruxolitinib is indicated for patients with intermediate- or high-risk MF, including those with primary MF, post-polycythemia vera MF, post–essential thrombocythemia MF. Momelotinib is indicated for patients with intermediate- or high-risk MF, including those with primary MF, post-polycythemia vera MF, and post–essential thrombocythemia MF in in adult patients with anemia.1
The
This analysis presented in Brooklyn was based on
- At the 6-month mark, the total cost of care favored ruxolitinib by$46,388.
- At the 1-year mark, the total cost of care favored ruxolitinib by $84,239.
- At the 2-year mark, the total cost of care favored ruxolitinib by $144,539.
Assumptions in the model. Authors wrote that the model assumed patients remained on therapy for the entire duration of the study or until death. It was limited to pharmacy- and transfusion-related costs, “to isolate costs associated with reductions in transfusion; other costs of care were assumed similar between ruxolitinib and momelotinib.”
Costs were sourced from a claims analysis. Pharmacy costs were based on dosing from product labels and acquisition costs listed in the Micromedex Red Book. The authors also presented some alternative transfusion scenarios to provide other cost examples.
Limitations. The authors wrote that although they lacked precise estimates for transfusion costs, all alternative scenarios “consistently resulted in cost savings with ruxolitinib.”
Also, the model did not incorporate other clinical benefits associated with ruxolitinib or momelotinib, “such as spleen response rate.”
The authors concluded that pharmacy costs for ruxolitinib remain favorable, “despite higher overall survival rates compared with momelotinib, which increase total pharmacy costs due to longer drug exposure.”
They noted that, “Higher transfusion independence rates among momelotinib patients drove the differences in transfusion costs but did not offset the larger reduction in pharmacy costs with ruxolitinib.”
Reference
- Gerds AT, Yu J, Tao C. Cost comparison of ruxolitinib and momelotinib in patients With myelofibrosis and anemia. Presented at: 16th International Congress on Myeloproliferative Neoplasms, held in Brooklyn, New York, October 24-25, 2024. Abstr 125.
- Harrison, C.N., Vannucchi, A.M., Recher, C. et al. Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: subgroup analysis of SIMPLIFY-2. Adv Ther. 2024;41:3722–3735.
https://doi.org/10.1007/s12325-024-02928-4 - Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Radiotherapy Raises Risk of Complications After Limb STS Surgery
September 16th 2025
- Overcoming Weight Bias in Health Care Systems
September 15th 2025